The modern human insulin segment has the largest market share in the global human insulin market is estimated to be the largest market during the forecasted period.

Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin.

The market for global human insulin is estimated at ~$25 billion in 2015 and is expected to grow at a CAGR of ~10-12% within forecasted period.

Human Insulin Market Segmentation:

Global Human Insulin market has been segmented on the basis of types which majorly includes modern human insulin, and traditional human insulin. The modern human insulin is further divided into; long acting human insulin, rapid acting human insulin, and premixed human insulin. Whereas, the traditional human insulin is again categorized into; short acting human insulin, and intermediate acting human insulin.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/951

Human Insulin Market Key Players

Biocon Ltd. (India), Tonghua Dongbao Pharmaceuticals Co., Ltd. (China), Adocia (France.), Merck & Co. (U.S.), Julphar (UAE), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc (U.K.), Oramed Pharmaceuticals, Inc. (Israel), Novo Nordisk A/S (Denmark), and others.

Human Insulin Market Regional Analysis

North America and EU regions are dominating the market over a period of time while, Asia is the fastest growing region for Human insulin Market in coming years

Increasing prevalence of diabetes and increasing R&D investment for more effective insulin are driving the growth of the human insulin market in North America. Diabetes has become one of the major public health problems in North America, due to increasing number of geriatric population and rising prevalence of obesity.

Diabetes is the major public health threat for the world. Prevalence of Type 2 diabetes is increasing rapidly in Asia-Pacific. According to a study conducted by National Centre for Biotechnology Information in 2012, approximately 60% of Asian population was suffering from diabetes. China is expected to have highest prevalence rate of diabetes, followed by India, due to rise in industrialization, urbanization and westernization.

Table Of Content

1. Report Prologue

2. Introduction

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.2.1 RESEARCH OBJECTIVE

2.2.2 ASSUMPTIONS

2.2.3 LIMITATIONS

2.3 MARKET STRUCTURE

2.4. MARKET SEGMENTATION

3. Research Methodology

3.1 RESEARCH PROCESS

3.2 PRIMARY RESEARCH

3.3 SECONDARY RESEARCH

3.4 MARKET SIZE ESTIMATION

3.5 FORECAST MODEL

TOC Continued….!

Browse Complete Report Details @

https://www.marketresearchfuture.com/reports/human-insulin-market-951

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]